Acumen Pharmaceuticals, Inc.
ABOS
$2.99
-$0.18-5.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -98.05% | -88.98% | -78.12% | 63.99% | 120.01% |
| Gross Profit | 98.05% | 88.98% | 78.12% | -63.99% | -120.01% |
| SG&A Expenses | -5.79% | -7.45% | -6.29% | -5.31% | -2.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.78% | -9.48% | 8.61% | 48.78% | 87.77% |
| Operating Income | 26.78% | 9.48% | -8.61% | -48.78% | -87.77% |
| Income Before Tax | 23.14% | 2.56% | -18.57% | -63.28% | -110.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.14% | 2.56% | -18.57% | -63.28% | -110.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.14% | 2.56% | -18.57% | -63.28% | -110.69% |
| EBIT | 26.78% | 9.48% | -8.61% | -48.78% | -87.77% |
| EBITDA | 26.79% | 9.48% | -8.62% | -48.83% | -87.85% |
| EPS Basic | 27.94% | 3.92% | -17.56% | -61.05% | -103.41% |
| Normalized Basic EPS | 27.94% | 3.92% | -17.57% | -61.08% | -103.45% |
| EPS Diluted | 27.94% | 3.92% | -17.56% | -61.05% | -103.41% |
| Normalized Diluted EPS | 27.94% | 3.92% | -17.57% | -61.08% | -103.45% |
| Average Basic Shares Outstanding | 6.37% | 1.73% | 0.91% | 1.58% | 3.93% |
| Average Diluted Shares Outstanding | 6.37% | 1.73% | 0.91% | 1.58% | 3.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |